Table 1.
Patient characteristics.
| All patients, n = 28 | |
|---|---|
| Sex, male (%)/female (%) | 25 (89%)/3 (11%) |
| Age, years (mean±SD) | 61 ± 8 |
| Etiology | |
| Viral hepatitis, n (%) | 12 (43%) |
| Alcohol, n (%) | 13 (46%) |
| Other, n (%) | 3 (11%) |
| Presence of ascites, n (%) | 5 (18%) |
| Varices | 9 (32%) |
| Small varices, n (%) | 4 (14%) |
| Large varices, n (%) | 5 (18%) |
| NSBB therapy | 3 (11%) |
| Propranolol, n (%) | 3 (11%) |
| INR | 1.2 ± 0.2 |
| Albumin, g/l | 37 ± 5 |
| Child-Pugh score, points (mean±SD) | 6 ± 1 |
| Child-Pugh A, n (%) | 22 (79%) |
| Child-Pugh B, n (%) | 6 (21%) |
| MELD score, points (mean±SD) | 10 ± 3 |
| PS | |
| PS 0, n (%) | 28 (100%) |
| BCLC stage | |
| A, n (%) | 4 (14%) |
| B, n (%) | 24 (86%) |
| Treatment group | |
| TACE alone, n (%) | 13 (46%) |
| TACE + bevacizumab, n (%) | 15 (54%) |
| HVPG, mmHg (median (IQR)) | 12 (9-19) |
| Level of portal hypertension | |
| No portal hypertension (HVPG < 6) | 5 (18%) |
| Subclinical portal hypertension (HVPG 6–9 mmHg) | 3 (11%) |
| Clinically significant portal hypertension (HVPG ≥ 10 mmHg) | 20 (71%) |
| Number of TACE sessions (mean±SD) | 4 ± 1 |
n: number of patients; BCLC: Barcelona Clinic Liver Cancer; PS: Performance Status; HVPG: hepatic venous pressure gradient; INR: international normalized ratio; MELD: Model for End-Stage Liver Disease; NAFLD: nonalcoholic fatty liver disease; NSBB: nonselective beta-blocker; TACE: transarterial chemoembolization.